Articles By Gail Dutton

41. International Incentives: Are They All They’re Cracked Up To Be? 8/1/2012

    Economic development agencies approach many pharmaceutical companies with incentives that included a wide range of grants, tax incentives, logistics help, and other enticements like streamline bureaucracy. 

42. Pharma Partnering: Two Views From China 6/28/2012

    Naturally, any potential partners must be vetted, but when working in regions that lack a history of pharmaceutical regulation, local partnering can be fraught with peril. China is a good example.

     

43. The Business Case For Pharmaceutical Serialization 6/1/2012

    Aside from regulatory compliance, pharmaceutical companies say the main benefit of serialization will be its support of anti-counterfeiting and diversion efforts, which translates to patient safety.

44. Planning Serialization For Pharmaceutical Manufacturers 4/30/2012

    The mandates to serialize all pharmaceutical products are as challenging for pharmaceutical manufacturers as the Y2K situation was to computer software engineers in 1999. Unlike the computer situation, however, the pharmaceutical industry has no defined protocols or solutions.

45. Fostering Asian Collaborations For Pharma Innovations 4/30/2012

    Astrazeneca’s collaboration with Asia extends their opportunity in pharmaceutical R&D and commercialization, because Asia lacks the entrenched drug development bureaucracy, which provides a relatively clean slate for pharma innovation.

46. The Long Road To Serialization And Track-And-Trace 4/12/2012

    The on-again, off-again efforts of the United States to implement serialization are on again, with a one-year phase-in scheduled to begin Jan. 1, 2015. At that point, California’s regulations become the de facto standard for the country. While large pharmaceutical companies are developing plans and piloting projects, smaller companies are maintaining a wait-and-see attitude.

47. Logistics Improving In Emerging Markets 2/13/2012

    Whether there for clinical trials, manufacturing, or market share, life sciences companies entering emerging and developing regions for the first time “tend to overlook the challenges associated with security, regulations, and the unique nature of the supply chain,” notes Bill Hook, VP of global strategy for UPS Healthcare Logistics.

48. Making The Most Of Industry/Academic Partnerships 11/1/2011

    Industry/academic partnerships are changing from the traditional hands-off approach to true collaborative efforts that better utilize the expertise and resources of each group.

49. Two Companies, Two New Paperless Labs 7/12/2011

    Paperless lab information management systems (LIMS) are becoming indispensible tools to help companies boost efficiency in analysis, documentation, and review. The gains, according to new users Carbogen Amcis AG and Hoffmann La Roche Basel, have been substantial, shaving 10 to 20 minutes from analysis, increasing report accuracy, and cutting analysis costs by as much as 25%.

50. Partnerships In Cold Chain Delivery 4/14/2011

    Against a backdrop of increasing regulations, fuel costs, and delays clearing customs (especially in developing regions), life sciences companies are turning to their logistics service providers (LSPs) to smooth the way. The providers are responding by forging deeper, more collaborative relationships with their shippers and by designing cold chain services with pharmaceuticals in mind.